FRI0092 EFFECTS OF BARICITINIB ON HAEMOGLOBIN AND RELATED LABORATORY PARAMETERS IN RHEUMATOID ARTHRITIS PATIENTS
Methods: Blood samples were analyzed at baseline and at each study visit for complete blood count, with more extensive phlebotomy at baseline (Wk 0) and Wks 12, 24, and 52 ( Figure 1 ). Data were aggregated from completed Phase 2 and 3 RA studies and one ongoing long-term extension study. EPO and reticulocyte (RET) data were collected from a Phase 2 RA study in Japan.
Results: Hgb levels below the gender-adjusted lower limit of normal (LLN) were often observed at baseline (25%). Small declines in Hgb were observed at Wk 2 and again at Wk 14 in bari (2 and 4 mg) and PBO-treated RA pts consistent with the volume and frequency of phlebotomy ( Figure 1 ). Initial decreases in Hgb were accompanied by declines in RET counts in bari-treated RA pts. Subsequent increases in Hgb were associated with increases in RET after Wk 8 and statistically significant dose-dependent increases vs. PBO in total iron (Fe), total iron binding capacity (TIBC) and EPO. Treatment-emergent (TE) shifts in Hgb from normal to <LLN were very common in all groups without differences across groups except for ADA, which was associated with a lower incidence of TE low Hgb. TE Common Terminology Criteria for Adverse Events (CTCAE) shifts in Hgb from <grade 3 to ≥grade 3 (<4.9 and ≥4.0 mmol/L; <8.0g/dL and ≥6.5g/dL) were uncommon and occurred in similar proportions of RA pts across groups (Table 1 ). Permanent discontinuation of study drug due to CTCAE ≥grade 3 Hgb shifts was uncommon (0.2%).
Conclusions:
The proportions of RA pts with TE abnormally low Hgb did not differ significantly between bari and PBO. Reductions in Hgb, including to ≥grade 3, were generally not associated with adverse outcomes. Despite concerns about the impact of JAK2 inhibition on EPO signaling, following initial declines incident to phlebotomy, dose-dependent increases in EPO, Fe, and TIBC with return to baseline in RET and Hgb were observed with bari. This suggests that homeostatic mechanisms counterbalance the pharmacologic effect of JAK inhibition on EPO signaling and that bari treatment enhances iron utilisation markers associated with anaemia of chronic disease. Methods: A total of 323 patients with RA, who performed dual-photon x-ray absorptiometry and carotid ultrasound, were included. We assessed RA disease activity, risk factors for atherosclerosis including hypertension, diabetes mellitus and dyslipidemia, presence of carotid plaque, carotid intima-media thickness (IMT), and BMD. BMD was measured at the lumbar spine (L-spine, L1-L4), femur neck (total femur neck) and distal forearm (total radius), and low BMD was defined as a T score of -1.0 or less.
Results:
The BMD in the L-spine, femur, and radius was significantly lower in patients with carotid plaques (n=152), compared to patients without plaques (n=171 
Conclusions:
The present study showed that carotid atherosclerosis was influenced by both disease activity and impaired bone health. Background: Rheumatoid arthritis (RA) treatment is usually done with nonbiological disease-modifying antirheumatic drugs (DMARDs), but the addition of a biological DMARD can be necessary. Biological drug therapy is usually prescribed following failure to achieve remission of the morbidity with one or more non-biological DMARDs. However, there is the possibility of using them as a first line in the initial phase, which there is the possibility of potentially altering its course or even reverting it to normality. Objectives: To determine the time Colombian patients with rheumatoid arthritis (RA) are treated with non-biological disease-modifying antirheumatic drugs (DMARDs) before changing to biological therapy. Methods: A retrospective cohort study that collected information about the start of antirheumatic treatment in patients of all ages with a diagnosis of RA until the change to biological DMARD therapy. Survival analysis using Kaplan-Meier curves, from 1 January 2007 until 31 December 2013 by SPSS 23.0 for Windows, was made. Results: A total of 3880 patients (75.3% women) with a mean age of 51.3 years started non-biological DMARDs. After 5 years, 234 patients (6.0%) initiated biological DMARD therapy in 17.5±13.9 months. Differences in the socio demographic and pharmacological characteristics between the two groups of treatment are shown in the table 1. The use of glucocorticoids was associated with a greater risk of biological DMARD initiation (OR: 2.49; 95% CI: 1.658-3.732; p<0.001), while the use of methotrexate (OR: 0.04; 95% CI: 0.014-0.108; p<0.001) and chloroquine (OR: 0.13; 95% CI: 0.092-0.187; p<0.001) reduced the risk of initiation.
After 5 years of non-biological DMARD therapy, 6.0% of people with RA started biological DMARDs. Receiving glucocorticoids, having any comedication, being treated in Bogota City or cities of the Colombian Atlantic coast affected the probability of switching to biological therapy in these patients. 
